HINGHAM, Mass. , Dec. 22, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has and will continue to implement key initiatives that will prepare the LIBERTY® Robotic System for commercialization. In conjunction with recently announced design freeze, Dr.
Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA HINGHAM, Mass. , Dec. 15, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) achieved the design freeze objective for the LIBERTY® Robotic System.
HINGHAM, Mass. , Nov. 19, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second patent application covering the Company’s LIBERTY ® Robotic System.
HINGHAM, Mass. , Oct. 06, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance covering the Company’s LIBERTY ® Robotic System. Globally, the Company now has 45 patents issued/allowed and 24
HINGHAM, Mass. , June 29, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that China has become the latest global jurisdiction to issue a Notice of Allowance (NOA) for the Company’s innovative ‘One & Done’ guidewire technology, joining the European Union along with those
HINGHAM, Mass. , June 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz , MD joined the Company’s Scientific Advisory Board (SAB). Dr. Weisz is a practicing interventional cardiologist and
HINGHAM, Mass. , June 04, 2021 (GLOBE NEWSWIRE) -- Global patent jurisdictions continue to recognize Microbot Medical Inc.’s (Nasdaq: MBOT) innovative ‘One & Done’ guidewire technology, as the Israel Intellectual Property Office has issued a Notice of Allowance (NOA).
HINGHAM, Mass. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent Office (JPO) that it intends to grant the Company a patent for its ‘One & Done’ guidewire technology for use with endoluminal interventions.
FDA Feedback Reflects Strength of Pre-Clinical Safety Data; Maintains Q3 2022 Projected Commencement of First-in-Human Clinical Trial HINGHAM, Mass. , Jan. 27, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced the completion of successful discussions with the U.S.
